Author

S. Gummuluru

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 4 Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

E. Muhlberger· 2 shared H. Akiyama· 2 shared J. Berrigan· 2 shared J. Olejnik· 2 shared A. A. Quinones-Molina· 1 shared A. J. Henderson· 1 shared A. L. Morey· 1 shared A. Nisa· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. Muhlberger

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Incorporation of 5 methylcytidine alleviates innate immune response to self-amplifying RNA vaccine

M. Komori, A. L. Morey, A. A. Quinones-Molina, J. Fofana, L. Romero, E. Peters, K. Matsuda, S. Gummuluru, J. F. Smith, W. Akahata, H. Akiyama

This study shows that incorporating 5-methylcytidine into saRNA vaccines reduces innate immune activation and adverse effects while maintaining strong immune responses.

bioRxiv · Nov 1, 2023 · PreprintImmunology

CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses

S. Jalloh, J. Olejnik, J. Berrigan, A. Nisa, E. L. Suder, H. Akiyama, M. Lei, S. Tyagi, Y. Bushkin, E. Muhlberger, S. Gummuluru

This study shows CD169 enables ACE2-independent SARS-CoV-2 entry in macrophages, leading to restricted viral replication and pro-inflammatory cytokine production.

bioRxiv · Mar 29, 2022Immunology

Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo.

J. Patten, P. T. Keiser, D. M. Gysi, G. Menichetti, H. Mori, C. J. Donahue, X. Gan, I. F. do Valle, K. Geoghegan-Barek, M. Anantpadma, R. Boytz, J. L. Berrigan, S. Hulsey-Stubbs, K. T. Ayazika, C. O'Leary, , R. A. Davey

The paper identifies 389 small molecules and 813 host targets that inhibit SARS-CoV-2 infection through in vitro and in vivo testing, using computational integration of drug activity and cellular networks.

bioRxiv · Apr 20, 2021 · PreprintMicrobiology

CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2

R. Amraei, M. Napoleon, W. Yin, J. Berrigan, E. Suder, G. Zhao, J. Olejnik, K. Chandler, C. Xia, S. Gummuluru, E. Muhlberger, V. Chitalia, C. Costello, N. Rahimi

This study identifies CD209L/L-SIGN and CD209/DC-SIGN as alternative receptors for SARS-CoV-2, capable of mediating virus entry into human cells, particularly in tissues with low ACE2 expression.

bioRxiv · Jun 22, 2020 · PreprintCell Biology

Strength of T cell signaling regulates HIV-1 replication and establishment of latency

M. Gagne, D. Michaels, G. Schiralli Lester, W. Wong, S. Gummuluru, A. J. Henderson

This study shows that strong T cell signaling promotes HIV-1 expression and inducible latency, while weak signaling leads to stable, refractory latency.

bioRxiv · Oct 1, 2018Microbiology